Compare iShares MSCI China ETF (MCHI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI China ETF trades at $52.53 (market cap $5.94B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI China ETF for 63 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MCHI | XBI | |
|---|---|---|
Market Cap | $5.94B | $10.11B |
Volume | 1,575,471 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $65.59 | $169.55 |
52-Week Low | $50.48 | $104.99 |
Typical Hold Time | 63 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $52.55, up 1.76% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights potential trade tensions ahead of the Trump-Xi summit, though corporate profits surged 26% in Q2 according to Zacks Investment Research (2026-09-08).
The outlook remains cautious due to China's macroeconomic pressures and global trade risks. Investment opportunity exists in MCHI's significant discount to historical valuations versus US indices, but risks include potential export controls and protectionism. The ETF's financial sector benefits from China's steepening yield curve, supporting bank and insurance holdings.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
